SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Eris Lifesciences - Quaterly Results

05 Aug 2022 Evaluate
The revenue for the June 2022 quarter is pegged at Rs. 3287.60 millions, about 7.33% up against Rs. 3062.96 millions recorded during the year-ago period.The Net proft of the company remain more or less same to Rs. 955.91  millions from Rs. 1067.20 millions ,decline by -10.43%.Operating profit surged to 1295.59 millions from the corresponding previous quarter of 1289.91 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 3287.60 3062.96 7.33 3287.60 3062.96 7.33 12157.30 11088.34 9.64
Other Income 33.72 64.47 -47.70 33.72 64.47 -47.70 289.89 99.98 189.95
PBIDT 1295.59 1289.91 0.44 1295.59 1289.91 0.44 5129.84 4273.12 20.05
Interest 72.26 4.63 1460.69 72.26 4.63 1460.69 29.91 7.78 284.45
PBDT 1223.33 1285.28 -4.82 1223.33 1285.28 -4.82 5099.93 4265.34 19.57
Depreciation 149.72 112.29 33.33 149.72 112.29 33.33 514.55 376.40 36.70
PBT 1073.61 1172.99 -8.47 1073.61 1172.99 -8.47 4585.38 3888.94 17.91
TAX 117.70 105.79 11.26 117.70 105.79 11.26 413.46 382.89 7.98
Deferred Tax -76.24 -102.42 -25.56 -76.24 -102.42 -25.56 -388.26 -318.95 21.73
PAT 955.91 1067.20 -10.43 955.91 1067.20 -10.43 4171.92 3506.05 18.99
Equity 135.97 135.78 0.14 135.97 135.78 0.14 135.93 135.78 0.11
PBIDTM(%) 39.41 42.11 -6.42 39.41 42.11 -6.42 42.20 38.54 9.49

Eris Lifesciences Share Price

1442.20 -4.30 (-0.30%)
20-Apr-2026 14:54 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.15
Dr. Reddys Lab 1234.50
Cipla 1232.65
Zydus Lifesciences 938.05
Lupin 2329.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×